Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00434850 · ClinicalTrials.gov registry record · Phase 2
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00434850: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00434850 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00434850, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the safety and efficacy of deoxyspergualin (DSG), an immunosuppressant drug, on post-transplant islet function in people with type 1 diabetes who have not responded to intensive insulin therapy.
Interventions
- DRUG Sirolimus
- BIOLOGICAL Allogeneic Pancreatic Islet Cells
- DRUG Deoxyspergualin
- BIOLOGICAL Antithymocyte globulin
- BIOLOGICAL Daclizumab or basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-10 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT00434850 record still lists
NCT00434850 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.
NCT00434850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00434850 about?
NCT00434850 is a clinical study titled "Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes". Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the safety and efficacy of deoxyspergualin (DSG), an immunosuppressant drug, on post-transplant islet function in...
What is the current status of trial NCT00434850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2006-10. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00434850?
The interventions under investigation include: Sirolimus (DRUG), Allogeneic Pancreatic Islet Cells (BIOLOGICAL), Deoxyspergualin (DRUG), Antithymocyte globulin (BIOLOGICAL), Daclizumab or basiliximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00434850?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00434850's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia